139 related articles for article (PubMed ID: 2285602)
1. Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents.
Mendelsohn J
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):889-92. PubMed ID: 2285602
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
3. The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.
Mendelsohn J
Semin Cancer Biol; 1990 Oct; 1(5):339-44. PubMed ID: 2103507
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.
Mendelsohn J
J Natl Cancer Inst Monogr; 1992; (13):125-31. PubMed ID: 1389685
[TBL] [Abstract][Full Text] [Related]
5. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
6. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.
Divgi CR; Welt S; Kris M; Real FX; Yeh SD; Gralla R; Merchant B; Schweighart S; Unger M; Larson SM
J Natl Cancer Inst; 1991 Jan; 83(2):97-104. PubMed ID: 1988695
[TBL] [Abstract][Full Text] [Related]
7. The epidermal growth factor receptor as a target for therapy in breast carcinoma.
Baselga J; Mendelsohn J
Breast Cancer Res Treat; 1994 Jan; 29(1):127-38. PubMed ID: 8018961
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.
Modjtahedi H; Eccles SA; Box G; Styles J; Dean CJ
Cell Biophys; 1993; 22(1-3):129-46. PubMed ID: 7534211
[TBL] [Abstract][Full Text] [Related]
9. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
[TBL] [Abstract][Full Text] [Related]
10. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody.
Goldenberg A; Masui H; Divgi C; Kamrath H; Pentlow K; Mendelsohn J
J Natl Cancer Inst; 1989 Nov; 81(21):1616-25. PubMed ID: 2795690
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
Modjtahedi H; Hickish T; Nicolson M; Moore J; Styles J; Eccles S; Jackson E; Salter J; Sloane J; Spencer L; Priest K; Smith I; Dean C; Gore M
Br J Cancer; 1996 Jan; 73(2):228-35. PubMed ID: 8546911
[TBL] [Abstract][Full Text] [Related]
12. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
Modjtahedi H; Affleck K; Stubberfield C; Dean C
Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
[TBL] [Abstract][Full Text] [Related]
13. The epidermal growth factor receptor as a target for cancer therapy.
Mendelsohn J
Endocr Relat Cancer; 2001 Mar; 8(1):3-9. PubMed ID: 11350723
[TBL] [Abstract][Full Text] [Related]
14. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.
Modjtahedi H; Eccles S; Box G; Styles J; Dean C
Br J Cancer; 1993 Feb; 67(2):254-61. PubMed ID: 7679281
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice.
Aboud-Pirak E; Hurwitz E; Pirak ME; Bellot F; Schlessinger J; Sela M
J Natl Cancer Inst; 1988 Dec; 80(20):1605-11. PubMed ID: 3193478
[TBL] [Abstract][Full Text] [Related]
17. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.
Modjtahedi H; Styles JM; Dean CJ
Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with antibodies to the EGF receptor.
Dean C; Modjtahedi H; Eccles S; Box G; Styles J
Int J Cancer Suppl; 1994; 8():103-7. PubMed ID: 8194887
[TBL] [Abstract][Full Text] [Related]
19. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
20. 5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells.
Caraglia M; Pinto A; Correale P; Zagonel V; Genua G; Leardi A; Pepe S; Bianco AR; Tagliaferri P
Ann Oncol; 1994 Mar; 5(3):269-76. PubMed ID: 7514437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
